Stem cells injected before amputation aim to prevent further surgery
NCT ID NCT02685098
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 37 times
Summary
This early-stage trial tested whether injecting donor stem cells into the leg muscles of people scheduled for amputation could prevent complications like poor wound healing and reduce the chance of needing more amputations. 81 patients with severe leg artery disease received the stem cell injections about a week before surgery. The main goal was to check safety, not yet to prove the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University
Indianapolis, Indiana, 46202, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
allogeneic bone marrow derived mesenchymal stem cells
What this could lead to
If successful, this approach could reduce wound complications and the need for repeat amputations after surgery.
What could go wrong
This is an early phase 1 trial focused on safety, so it is too soon to know if it works. The stem cells may not survive or provide benefit, and there are risks of adverse events.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.